| The influence of hepatitis C virus genetic region on phylogenetic clustering analysis FMJ Lamoury, B Jacka, S Bartlett, RA Bull, A Wong, J Amin, J Schinkel, ... PloS one 10 (7), e0131437, 2015 | 50 | 2015 |
| Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project SR Bartlett, P Fox, H Cabatingan, A Jaros, C Gorton, R Lewis, E Priscott, ... Clinical Infectious Diseases 67 (3), 460-463, 2018 | 45 | 2018 |
| Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review SR Bartlett, J Grebely, AA Eltahla, JD Reeves, AYM Howe, V Miller, ... Hepatology communications 1 (5), 379-390, 2017 | 41 | 2017 |
| Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE Study M Martinello, J Yee, SR Bartlett, P Read, D Baker, JJ Post, R Finlayson, ... Clinical Infectious Diseases 71 (6), 1502-1510, 2020 | 26* | 2020 |
| The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals SR Bartlett, A Yu, N Chapinal, C Rossi, Z Butt, S Wong, M Darvishian, ... Liver International 39 (12), 2261-2272, 2019 | 24 | 2019 |
| A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies SR Bartlett, JO Wertheim, RA Bull, GV Matthews, FMJ Lamoury, ... Journal of viral hepatitis 24 (5), 404-411, 2017 | 21 | 2017 |
| Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply M Bonn, A Palayew, S Bartlett, TD Brothers, N Touesnard, M Tyndall Journal of studies on alcohol and drugs 81 (5), 556-560, 2020 | 20 | 2020 |
| Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral treatment in … S Bajis, J Grebely, B Hajarizadeh, T Applegate, AD Marshall, ... Journal of viral hepatitis 27 (3), 281-293, 2020 | 16 | 2020 |
| Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations C Rossi, D Jeong, S Wong, G McKee, ZA Butt, J Buxton, J Wong, ... Journal of hepatology 71 (6), 1116-1125, 2019 | 16 | 2019 |
| Real-world effectiveness of sofosbuvir/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: a population-based cohort study J Wilton, S Wong, A Yu, A Ramji, D Cook, ZA Butt, M Alvarez, M Binka, ... Open forum infectious diseases 7 (3), ofaa055, 2020 | 10 | 2020 |
| HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection SR Bartlett, B Jacka, RA Bull, F Luciani, GV Matthews, FMJ Lamoury, ... Infection, Genetics and Evolution 37, 252-258, 2016 | 10 | 2016 |
| Loss to follow‐up: a significant barrier in the treatment cascade with direct‐acting therapies M Darvishian, S Wong, M Binka, A Yu, A Ramji, EM Yoshida, J Wong, ... Journal of viral hepatitis 27 (3), 243-260, 2020 | 6 | 2020 |
| Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment N Janjua, J Wilton, D Cook, S Wong, Z Butt, S Bartlett, M Pearce, A Ramji, ... Journal of Hepatology 73, S356-S357, 2020 | 3* | 2020 |
| A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015 SR Bartlett, TL Applegate, BP Jacka, M Martinello, FMJ Lamoury, M Danta, ... Journal of the International AIDS Society 22 (2), e25222, 2019 | 3 | 2019 |
| Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types FMJ Lamoury, S Bartlett, B Jacka, B Hajarizadeh, J Grebely, GV Matthews, ... The Journal of molecular diagnostics 17 (5), 583-589, 2015 | 3 | 2015 |
| Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of Escherichia coli S Bartlett, J Seeliger, JN Burnell Current Topics in Biochemical Research 14, 77-83, 2012 | 3 | 2012 |
| Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada H Samji, A Yu, S Wong, J Wilton, M Binka, M Alvarez, S Bartlett, M Pearce, ... International Journal of Drug Policy 86, 102989, 2020 | 2 | 2020 |
| Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct‐Acting Antiviral Era SR Bartlett, J Buxton, A Palayew, CA Picchio, NZ Janjua, N Kronfli Clinical Liver Disease 17 (2), 75, 2021 | 1 | 2021 |
| Disparities in hepatitis C care across Canadian provincial prisons: implications for hepatitis C micro-elimination N Kronfli, C Dussault, S Bartlett, D Fuchs, K Kaita, K Harland, B Martin, ... Canadian Liver Journal, e20200035, 2021 | 1 | 2021 |
| “The Times They Are a-Changin’”: Addressing Common Misconceptions About the Role of Safe Supply in North America’s Overdose Crisis M Bonn, A Palayew, S Bartlett, TD Brothers, N Touesnard, M Tyndall Journal of studies on alcohol and drugs 82 (1), 158-160, 2021 | 1 | 2021 |
Naveed Zafar JanjuaBritish Columbia Centre for Disease Control & University of British ColumbiaVerified email at bccdc.ca
